Holen Sie sich die Stockscreener-App
6.645
0.68%
0.035
CorMedix Inc Aktie (CRMD) Neueste Nachrichten
How The CorMedix (CRMD) Investment Story Is Shifting As Analyst Targets Reset - Yahoo Finance
How Cormedix Inc. (CRMD) Affects Rotational Strategy Timing - Stock Traders Daily
Levels Update: Can CorMedix Inc outperform under higher oil pricesWeekly Stock Analysis & Free Accurate Trade Setup Notifications - baoquankhu1.vn
CRMD News | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
Is CorMedix (CRMD) Now Offering Value After Sharp Share Price Declines? - simplywall.st
US Market Recap: What is the target price for CorMedix Inc stock2026 Stock Rankings & Daily Profit Focused Stock Screening - baoquankhu1.vn
Street Watch: Is CorMedix Inc a stock for growth or value investors2026 Momentum Check & Fast Momentum Entry Tips - baoquankhu1.vn
Aug Shorts: What makes CorMedix Inc stock attractive todayWeekly Trend Summary & Proven Capital Preservation Tips - baoquankhu1.vn
Assessing CorMedix (CRMD) Valuation After Recent Share Price Weakness And Long Term Gains - simplywall.st
CRMD Stock Price, Quote & Chart | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
Why did CRMD stock tumble over 11% today? - MSN
CorMedix at Citizens Life Sciences: Strategic Expansion and Growth By Investing.com - Investing.com Canada
CRMD: REZZAYO and DefenCath drive growth, with Melinta boosting revenue and new markets targeted - TradingView
CorMedix at Leerink Conference: Strategic Evolution and Market Potential By Investing.com - Investing.com Nigeria
Cormedix Earnings Call: Peak DEFENCATH, Tough Road Ahead - TipRanks
CorMedix at Leerink Conference: Strategic Evolution and Market Potential - Investing.com
CRMD: Diversified specialty pharma advancing REZZAYO and DefenCath, with strong growth catalysts ahead - TradingView
CorMedix reports Q4 revenue of $128.6M, reaffirms 2026 guidance - Investing.com Nigeria
What is CorMedix Inc.’s book value per shareMarket Weekly Review & Fast Moving Stock Trade Plans - baoquankhu1.vn
Strength Seen in CorMedix (CRMD): Can Its 21.7% Jump Turn into More Strength? - MSN
CorMedix (CRMD) Is Down 9.4% After Reaffirming 2026 Guidance and Reporting Profit SwingWhat's Changed - simplywall.st
CorMedix Q4 2025 earnings preview - MSN
CorMedix outlines $300M–$320M revenue and $100M–$125M EBITDA targets for 2026 amid DefenCath transition and Melinta integration - MSN
CorMedix nears an 11-month low after earnings miss - MSN
CorMedix (CRMD) lags Q4 earnings estimates - MSN
CorMedix Therapeutics 2026: Portfolio Expansion, Financial Highlights, DefenCath Launch & Growth Pipeline in Specialty Pharma 1234567 - Minichart
CorMedix Strikes $300M Deal For Melinta Therapeutics, Retail Calls It A ‘Wonderful Acquisition’ - MSN
CorMedix Inc. (CRMD) Acquires Melinta Therapeutics to Expand Hospital-Focused Portfolio - MSN
Leerink cuts CorMedix stock price target on expense adjustments - Investing.com India
Update Recap: What is the target price for CorMedix Inc stockWeekly Risk Report & Real-Time Market Sentiment Reports - baoquankhu1.vn
CorMedix 2025 Financial Results: $163.1M Profit, $311.7M RevenueNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
CorMedix Reaffirms DefenCath 2027 Sales and Outlook - TipRanks
Leerink cuts CorMedix stock price target on expense adjustments By Investing.com - Investing.com South Africa
Assessing CorMedix (CRMD) Valuation After Recent Share Price Weakness And Growth Expectations - Yahoo Finance
CorMedix Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
CorMedix Inc. (NASDAQ:CRMD) Q4 2025 Earnings Call Transcript - Insider Monkey
Cormedix Earnings Review: Q4 Summary - Sahm
CorMedix Buyback And REZZAYO Data Shape Valuation And Risk Profile - Yahoo Finance
CorMedix reports Q4 revenue of $128.6M, reaffirms 2026 guidance By Investing.com - Investing.com Canada
CorMedix Q4 Revenue Improves; Reaffirms FY26 Outlook; Plans To Report Phase III REZZAYO Data In Q2 - Nasdaq
Truist reiterates CorMedix stock rating on steady guidance - Investing.com India
Truist reiterates CorMedix stock rating on steady guidance By Investing.com - Investing.com South Africa
CorMedix (CRMD) Q4 2025 Earnings Call Transcript - AOL.com
CorMedix (CRMD) Valuation Check After Recent Share Price Swings And Melinta Acquisition Narrative - simplywall.st
Why Did CRMD Stock Tumble Over 11% Today? - Stocktwits
CorMedix Shares Fall After Q4 Profit Miss - marketscreener.com
CorMedix stock drops after earnings: is this dip a buy before key catalyst? - TradingView
CorMedix: Fourth Quarter Financial Results Overview - Bitget
CorMedix stock falls after earnings miss (CRMD:NASDAQ) - Seeking Alpha
Earnings call transcript: CorMedix Q4 2025 results miss EPS, stock dips - Investing.com Nigeria
Cormedix Stock Pre-Market (+6.2%) : Technical Move Ahead of Key Q2 Catalyst - Trefis
Earnings call transcript: CorMedix Q4 2025 results miss EPS, stock dips By Investing.com - Investing.com South Africa
CorMedix (CRMD) reports higher Q4 2025 profit on strong revenue growth - AlphaStreet
0.99%
3.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):